| Bioactivity | Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively. |
| Invitro | Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases[1]. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol[2].Flavopiridol (Alvocidib) also inhibits cyclin E1 and induces apoptosis[4]. |
| Name | Flavopiridol |
| CAS | 146426-40-6 |
| Formula | C21H20ClNO5 |
| Molar Mass | 401.84 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
Flavopiridol
CAS: 146426-40-6 F: C21H20ClNO5 W: 401.84
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s o
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.